Eli Lilly's (LLY) New Tirzepatide Results Suggest A Very Differentiated Product - Wolfe Research

February 18, 2021 7:02 AM EST
Get Alerts LLY Hot Sheet
Price: $189.25 +1.79%

Rating Summary:
    19 Buy, 10 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wolfe Research analyst Tim Anderson reiterated an Outperform rating and $235.00 price target on Eli Lilly (NYSE: LLY) after the company updated top line data on diabetes pipeline drug, tirzepatide, from the phase 3 SURPASS-3 and -5 trials. These data confirm the profile shown previously in phase 2 studies and in the phase 3 SURPASS-1 trial.

The analyst stated "We upgraded LLY from Peer Perform to Outperform on December 10th, on the back of tirzepatide de-risking following the first ph3 read out from SURPASS-1. LLY had been a name we were leaning constructive on but were apprehensive to step in front of tirzepatide from a risk:reward standpoint, in case there were any unexpected hiccups with the data. As additional trials read out, that risk is increasingly behind us. The drug is likely to launch in 2022 and offers franchise durability after Trulicity goes off-patent at the start of 2028."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $206.46 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

S3, S1